25th Anniversary of the International Long-QT Syndrome Registry
2005; Lippincott Williams & Wilkins; Volume: 111; Issue: 9 Linguagem: Inglês
10.1161/01.cir.0000157069.91834.da
ISSN1524-4539
AutoresArthur J. Moss, Peter J. Schwartz,
Tópico(s)Receptor Mechanisms and Signaling
ResumoHomeCirculationVol. 111, No. 925th Anniversary of the International Long-QT Syndrome Registry Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUB25th Anniversary of the International Long-QT Syndrome RegistryAn Ongoing Quest to Uncover the Secrets of Long-QT Syndrome Arthur J. Moss, MD and Peter J. Schwartz, MD Arthur J. MossArthur J. Moss From the Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Rochester, NY (A.J.M.), and the Department of Cardiology, IRCCS Policlinico S. Matteo and University of Pavia, Pavia, Italy (P.J.S.). and Peter J. SchwartzPeter J. Schwartz From the Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Rochester, NY (A.J.M.), and the Department of Cardiology, IRCCS Policlinico S. Matteo and University of Pavia, Pavia, Italy (P.J.S.). Originally published8 Mar 2005https://doi.org/10.1161/01.CIR.0000157069.91834.DACirculation. 2005;111:1199–1201Today, it is exceptional to find a major cardiology congress without a session devoted to the long-QT syndrome (LQTS), but it was quite different 25 years ago when the minuscule knowledge about LQTS was paralleled only by the minute number of investigators interested in what seemed to be little more than a medical oddity. Partly by chance, the two of us had actually and independently developed a rather burning interest and curiosity for this often lethal hereditary disorder that is spiced by several unique features.1–4 We joined forces with the goal of unraveling this mysterious disease by establishing a prospective International Registry for LQTS. The main objectives were those to gain insight into the natural history, clinical course, and efficacy of current and novel therapies. When molecular biology techniques matured to the point of making possible the identification of disease-causing genes and disease-causing mutations, what became essential was the availability of numerous and well-developed clinical pedigrees providing clear separation between "affected" and "nonaffected" individuals. This is what the Registry was able to provide and where it played a decisive role in sharing with molecular biologists the ideal material for their analysis.In 1979, when the Registry was established, it did not escape us that this long-term project was likely to contribute to a better understanding and management of LQTS. Quite frankly, however, we did not anticipate the explosion of knowledge that would result from the genetic and molecular findings of the 1990s and the central role that the Registry, with its well-defined clinical phenotypes and family pedigrees, would play in uncovering the secrets of this disorder. Additionally, we could not have fathomed the now clear evidence that LQTS indeed represents a paradigm for the understanding of sudden cardiac death in more common cardiac diseases.ObjectivesOur primary objective with the International LQTS Registry was to gain insight into the natural history and clinical course of this hereditary repolarization disorder so that more effective therapy could be rendered to prevent the syncope and sudden death events that frequently accompanied LQTS.ImpactThe International LQTS Registry has enhanced our knowledge base of an infrequently occurring cardiac disorder, and it has become a paradigm for studying such conditions. The diagnostic criteria for LQTS have been established.5 The cardiologists associated with the Registry continue to offer physicians from around the world an opportunity to obtain advice on how to manage their LQTS patients. This exchange between the Registry cardiologists and physicians became a mutually beneficial interaction because these physicians also contributed clinical data to the Registry by willingly completing enrollment and yearly follow-up data forms. This approach allowed us to gather information on an impressive number of patients and, of crucial importance for the subsequent genetic developments, on first- and second-degree family relatives. Over the years, the growing knowledge in LQTS was shared with the profession through scientific publications, chapters in cardiology textbooks, personal communications, and recently, an Internet-based virtual LQTS symposium (http://lqts-symposium.org).Subsequently, similar types of registries were established by interested investigators for other uncommon cardiac disorders, including hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and Brugada syndrome. It is gratifying to know that the International LQTS Registry helped to pave the way for scientific progress in the difficult field of uncommon diseases.Molecular GeneticsBy the early 1990s, molecular biology had made impressive progress. The new genetic techniques, especially linkage analysis and detection of DNA sequence differences, were offering a realistic potential for the identification of disease genes and disease-causing mutations. There was only one limiting step, and not a small one. These techniques, as powerful as they were, still depended for their success on the availability of well-developed clinical pedigrees. Carefully studied large family trees with clear separation between affected and nonaffected individuals were essential. This is where the Registry, with its many large families and myriad of small families together with a quantitative QTc diagnostic marker and well-defined clinical phenotypes, played a decisive role in offering molecular biologists ideal material on which to perform their analyses.It was on this background that Keating and associates made their fundamental discoveries.6–10 It seems fair to say that in modern cardiology, few findings have had such fruitful consequences as the identification of the first 3 LQTS genes (KvLQT1 [LQT1], hERG [LQT2], and SCN5A [LQT3]). Merit is often not disjointed from good luck. The first series of genes identified with LQTS were all encoding cardiac ion channels, and it is fortunate that techniques already existed that allowed for functional evaluation of the mutant genes by cellular expression studies. These studies provided the evidence on how a specific mutation, by altering cardiac electrophysiology and the balance between inward and outward currents, was affecting the cardiac action potential, thus explaining how these mutations result in the lengthening of ventricular repolarization coded as QT prolongation.LQTS and Drug-Induced QT ProlongationIn 1982,11 we highlighted the role of drug-induced QT prolongation in delayed ventricular repolarization disorders. We pointed out that flagrant QT prolongation and syncope can occur at ordinary therapeutic doses of quinidine and raised the possibility that "quinidine therapy may exacerbate an underlying repolarization abnormality, possibly a subclinical forme fruste of idiopathic LQTS with incomplete expression."Concurrent with the advance in the molecular genetics of LQTS and the realization that reduction in the IKr current involving mutations in the hERG gene was responsible for LQT2, drug-induced QT prolongation involving terfenadine, cisapride, and other medications surfaced with documented torsade de pointes and sudden death. The similarity of acquired drug-induced prolongation of ventricular repolarization with the LQT2 form of LQTS was appreciated. The information acquired from the Registry about the cellular and molecular mechanisms involved in ion channel currents contributed to our enhanced understanding of drug-induced repolarization disorders.Findings From the RegistryThe Registry, with its expanding number of genotyped families, has provided an opportunity to study the clinical aspects and explore the genotype-phenotype relationships in this unique cardiovascular disorder. The first publication of findings from the Registry occurred in 1985 when we highlighted the risk factors for cardiac events in 196 LQTS patients.12 By 1991, we expanded the prospective study of the clinical course of this disorder to 1016 affected individuals in 328 LQTS families.13 Important findings from the Registry during the past decade have included the following: age- and sex-related differences in the clinical manifestations of LQTS14; influence of pregnancy on the risk for cardiac events in LQTS15; ECG T-wave patterns in genetically distinct forms of LQTS16; clinical course of LQTS by genotype17; the spectrum of mutations in LQTS genes18; increased risk associated with mutations in the pore region of the hERG gene19; role played by physical exercise, emotions, arousal, and rest/sleep as triggers and facilitators for syncope and sudden cardiac death in LQT1, LQT2, and LQT320–22; effectiveness of β-blocker therapy, particularly in patients with LQT1 and LQT2 genotypes23; potential gene-specific usefulness of sodium channel blockers (mexiletine and flecainide) in the treatment of patients with the LQT3 mutations24,25; life-saving benefit from the implanted defibrillator in high-risk LQTS patients26; and left cardiac sympathetic denervation in the management of high-risk LQTS patients.27We initially thought that the clinical benefit of left-sided sympathectomy might have come from either a correction of a hypothesized left-sided dominance of sympathetic innervation or, in the case of a yet undefined "myocardial abnormality" (subsequently found to be represented by the mutations in cardiac ion channel genes), from removal of an arrhythmogenic trigger. Our current view is that the second hypothesis was correct and that the benefit of left cardiac sympathetic denervation reflects primarily the interruption of the major source of norepinephrine release at the ventricular level.Key to the success of the International LQTS Registry was our good fortune to have an outstanding group of committed multidisciplinary investigators who have been associated with the program through several decades.LimitationsAll registries have limitations. From the beginning we prespecified the data to be collected, but the initial data collection reflected our limited understanding of the disorder. As we gained more insight into LQTS and its clinical and genetic heterogeneity, we expanded the type and extent of collected data, especially during yearly follow-ups. Our experience with sophisticated data management grew as the Registry expanded. Early on we recognized the need for biostatistical and statistical-genetic expertise. Although we collected prospective data and based our primary analyses on prespecified hypotheses, several of our important secondary studies involved retrospective analyses with the need to control for relevant covariates. The Registry utilized observational data, with all the potential problems of bias. Because the time origin was usually birth when doing clinical course studies, we appreciated the need for proportional-hazard survivorship analyses using time-dependent end points for syncope, aborted cardiac arrest, and death. Randomized placebo-controlled clinical trials are not practical when dealing with a rare cardiac disorder with relatively infrequent cardiac events, and therefore we learned to control for various types of bias as best we could through statistical adjustment techniques when evaluating the safety and efficacy of β-blocker, left cardiac sympathetic denervation, and implanted defibrillator therapies.Challenges for the FutureAdditional new genes and new genetic mechanisms need to be uncovered, modifier genes that explain the variable ventricular repolarization duration and/or the variable severity of clinical manifestations in individuals with the same mutation have yet to be identified, gene-specific and mutation-specific therapy is presently in its infancy, and the brain-heart connection with regard to emotional triggers of cardiac events needs more neurophysiologically based investigations. Our quest for uncovering the secrets of LQTS continues.This work was supported in part by research grants HL-33843 and HL-51618 from the National Institutes of Health, Bethesda, Md.FootnotesCorrespondence to Arthur J. Moss, MD, Heart Research Follow-up Program, Box 653, University of Rochester Medical Center, Rochester, NY 14642. E-mail [email protected] References 1 Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 1971; 285: 903–904.CrossrefMedlineGoogle Scholar2 Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J. 1975; 89: 45–50.CrossrefMedlineGoogle Scholar3 Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975; 89: 378–390.CrossrefMedlineGoogle Scholar4 Moss AJ, Schwartz PJ. Sudden death and the idiopathic long Q-T syndrome. Am J Med. 1979; 66: 6–7.CrossrefMedlineGoogle Scholar5 Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993; 88: 782–784.CrossrefMedlineGoogle Scholar6 Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991; 252: 704–706.CrossrefMedlineGoogle Scholar7 Keating M, Dunn C, Atkinson D, Timothy K, Vincent GM, Leppert M. Consistent linkage of the long-QT syndrome to the Harvey ras-1 locus on chromosome 11. Am J Hum Genet. 1991; 49: 1335–1339.MedlineGoogle Scholar8 Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995; 80: 805–811.CrossrefMedlineGoogle Scholar9 Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80: 795–803.CrossrefMedlineGoogle Scholar10 Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996; 12: 17–23.CrossrefMedlineGoogle Scholar11 Moss AJ, Schwartz PJ. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Modern Concepts Cardiovasc Dis. 1982; 51: 85–90.MedlineGoogle Scholar12 Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E. The long QT syndrome: a prospective international study. Circulation. 1985; 71: 17–21.CrossrefMedlineGoogle Scholar13 Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr, Robinson JL, Benhorin J, Choi S. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991; 84: 1136–1144.CrossrefMedlineGoogle Scholar14 Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann GM, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998; 97: 2237–2244.CrossrefMedlineGoogle Scholar15 Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, Schwartz PJ, Andrews M, for the LQTS Investigators. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. Circulation. 1998; 97: 451–456.CrossrefMedlineGoogle Scholar16 Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995; 92: 2929–2934.CrossrefMedlineGoogle Scholar17 Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ, for the International Long-QT Syndrome Registry Research Group. Influence of genotype on the clinical course of the long-QT syndrome. N Engl J Med. 1998; 339: 960–965.CrossrefMedlineGoogle Scholar18 Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000; 102: 1178–1185.CrossrefMedlineGoogle Scholar19 Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, Towbin JA, Keating MT, Priori SG, Schwartz PJ, Vincent GM, Robinson JL, Andrews ML, Feng C, Hall WJ, Medina A, Zhang L, Wang Z. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 2002; 105: 794–799.LinkGoogle Scholar20 Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz PJ, Vincent GM, Benhorin J, Locati Heilbron E, Towbin JA, Priori SG, Napolitano C, Zhang L, Medina A, Andrews ML, Timothy K. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol. 1999; 84: 876–879.CrossrefMedlineGoogle Scholar21 Ali RHH, Zareba W, Moss AJ, Schwartz PJ, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Towbin JA, Hall WJ, Robinson JL, Andrews ML, Zhang L, Timothy K, Medina A. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol. 2000; 85: 457–461.CrossrefMedlineGoogle Scholar22 Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AAM, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001; 103: 89–95.LinkGoogle Scholar23 Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000; 101: 616–623.CrossrefMedlineGoogle Scholar24 Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin AJ, Keating MT, Hammoude H, Brown AM, Chen LK, Colatsky TJ. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995; 92: 3381–3386.CrossrefMedlineGoogle Scholar25 Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A: ΔKPQ mutation. Ann Noninvasive Electrocardiol. 2001; 6: 153–158.CrossrefMedlineGoogle Scholar26 Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003; 14: 337–341.CrossrefMedlineGoogle Scholar27 Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004; 109: 1826–1833.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yeung C and Baranchuk A (2022) Overview of torsades de pointes Torsades de Pointes, 10.1016/B978-0-12-821446-6.00013-4, (1-26), . Schwartz P and Ackerman M (2022) Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias, European Heart Journal, 10.1093/eurheartj/ehac134, 43:22, (2096-2102), Online publication date: 6-Jun-2022. Schwartz P (2020) 1970–2020: 50 years of research on the long QT syndrome—from almost zero knowledge to precision medicine, European Heart Journal, 10.1093/eurheartj/ehaa769, 42:11, (1063-1072), Online publication date: 14-Mar-2021. Gnecchi M, Sala L and Schwartz P (2021) Precision Medicine and cardiac channelopathies: when dreams meet reality, European Heart Journal, 10.1093/eurheartj/ehab007, 42:17, (1661-1675), Online publication date: 1-May-2021. Raja J, Menon S, Venkata D, Unnikrishnan K and Namboodiri N (2021) Congenital long QT syndrome and patent ductus arteriosus: A rare surgical scenario, Annals of Pediatric Cardiology, 10.4103/apc.APC_146_19, 14:1, (85), . Márquez M (2021) The Quest for the Evidence of Effectiveness of Implantable Cardioverter-Defibrillators in Long QT Syndrome, Journal of the American College of Cardiology, 10.1016/j.jacc.2021.09.020, 78:21, (2089-2091), Online publication date: 1-Nov-2021. Wang M, Peterson D, Rosero S, McNitt S, Rich D, Seplaki C, Polonsky B, Goldenberg I and Zareba W (2021) Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome, Journal of the American College of Cardiology, 10.1016/j.jacc.2021.09.017, 78:21, (2076-2088), Online publication date: 1-Nov-2021. Gomes J (2020) The Channelopathies and Sudden Death Heart Rhythm Disorders, 10.1007/978-3-030-45066-3_19, (267-289), . Biso S, Naksuk N and Darbar D (2020) Genetic and Molecular Basis of Cardiac Arrhythmias Management of Cardiac Arrhythmias, 10.1007/978-3-030-41967-7_3, (75-96), . Clemens D, Tester D, Giudicessi J, Bos J, Rohatgi R, Abrams D, Balaji S, Crotti L, Faure J, Napolitano C, Priori S, Probst V, Rooryck-Thambo C, Roux-Buisson N, Sacher F, Schwartz P, Silka M, Walsh M and Ackerman M (2019) International Triadin Knockout Syndrome Registry, Circulation: Genomic and Precision Medicine, 12:2, Online publication date: 1-Feb-2019. Crotti L, Spazzolini C, Tester D, Ghidoni A, Baruteau A, Beckmann B, Behr E, Bennett J, Bezzina C, Bhuiyan Z, Celiker A, Cerrone M, Dagradi F, De Ferrari G, Etheridge S, Fatah M, Garcia-Pavia P, Al-Ghamdi S, Hamilton R, Al-Hassnan Z, Horie M, Jimenez-Jaimez J, Kanter R, Kaski J, Kotta M, Lahrouchi N, Makita N, Norrish G, Odland H, Ohno S, Papagiannis J, Parati G, Sekarski N, Tveten K, Vatta M, Webster G, Wilde A, Wojciak J, George A, Ackerman M and Schwartz P (2019) Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry, European Heart Journal, 10.1093/eurheartj/ehz311, 40:35, (2964-2975), Online publication date: 14-Sep-2019. Nisam S, Cannom D and Zareba W (2018) ARTHUR J. MOSS MD, Journal of Cardiovascular Electrophysiology, 10.1111/jce.13489, 29:4, (511-513), Online publication date: 1-Apr-2018. Zareba W (2018) Arthur J. Moss (1931-2018), Annals of Noninvasive Electrocardiology, 10.1111/anec.12556, 23:3, (e12556), Online publication date: 1-May-2018. Klein H, Zareba W and Kutyifa V (2018) In memoriam Dr Arthur J. Moss, EP Europace, 10.1093/europace/euy086, 20:6, (1060-1062), Online publication date: 1-Jun-2018. Goldenberg I and Moss A (2017) Risk Stratification for Sudden Cardiac Death in Individuals Without Structural Disease, Circulation: Arrhythmia and Electrophysiology, 10:10, Online publication date: 1-Oct-2017. Maltese P, Orlova N, Krasikova E, Emelyanchik E, Cheremisina A, Kuscaeva A, Salmina A, Miotto R, Bonizzato A, Guerri G, Zuntini M, Nicoulina S and Bertelli M (2017) Gene-Targeted Analysis of Clinically Diagnosed Long QT Russian Families, International Heart Journal, 10.1536/ihj.16-133, 58:1, (81-87), . Schwartz P, Dagradi F and Castelletti S (2017) Evolution in Managing Long QT Syndrome, Journal of the American College of Cardiology, 10.1016/j.jacc.2017.06.004, 70:4, (463-465), Online publication date: 1-Jul-2017. Vandenberg J, Perry M and Hill A (2017) Recent advances in understanding and prevention of sudden cardiac death, F1000Research, 10.12688/f1000research.11855.1, 6, (1614) Immanuel S, Sadrieh A, Baumert M, Couderc J, Zareba W, Hill A and Vandenberg J (2016) T-wave morphology can distinguish healthy controls from LQTS patients, Physiological Measurement, 10.1088/0967-3334/37/9/1456, 37:9, (1456-1473), Online publication date: 1-Sep-2016. Perry M, Ng C, Phan K, David E, Steer K, Hunter M, Mann S, Imtiaz M, Hill A, Ke Y and Vandenberg J (2016) Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations, The Journal of Physiology, 10.1113/JP271805, 594:14, (4031-4049), Online publication date: 15-Jul-2016. Ruwald M, Xu Parks X, Moss A, Zareba W, Baman J, McNitt S, Kanters J, Shimizu W, Wilde A, Jons C and Lopes C (2016) Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1, Heart Rhythm, 10.1016/j.hrthm.2015.08.033, 13:1, (122-131), Online publication date: 1-Jan-2016. Yousuf O, Chrispin J, Tomaselli G and Berger R (2015) Clinical Management and Prevention of Sudden Cardiac Death, Circulation Research, 116:12, (2020-2040), Online publication date: 5-Jun-2015. Lowengrub K, Moss D, Moss D and Moss A (2015) Long QT Syndrome: How Effective Therapy in a Single Patient Favorably Influenced the Long-Term Clinical Course and Genetic Understanding of this Hereditary Disorder, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2015.08.002, 58:2, (221-226), Online publication date: 1-Sep-2015. Rigatti S (2015) The Long QT Syndrome: A Review and Mortality Analysis, Journal of Insurance Medicine, 10.17849/insm-45-02-081-087.1, 45:2, (81-87), Online publication date: 1-Jan-2015. Gonzalez F, Veneziano M, Puggina A and Boccia S (2015) A Systematic Review on the Cost-Effectiveness of Genetic and Electrocardiogram Testing for Long QT Syndrome in Infants and Young Adults, Value in Health, 10.1016/j.jval.2015.03.1788, 18:5, (700-708), Online publication date: 1-Jul-2015. Spencer C, Baba S, Nakamura K, Hua E, Sears M, Fu C, Zhang J, Balijepalli S, Tomoda K, Hayashi Y, Lizarraga P, Wojciak J, Scheinman M, Aalto-Setälä K, Makielski J, January C, Healy K, Kamp T, Yamanaka S and Conklin B (2014) Calcium Transients Closely Reflect Prolonged Action Potentials in iPSC Models of Inherited Cardiac Arrhythmia, Stem Cell Reports, 10.1016/j.stemcr.2014.06.003, 3:2, (269-281), Online publication date: 1-Aug-2014. Ke Y, Hunter M, Ng C, Perry M and Vandenberg J (2014) Role of the Cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) Domain in Trafficking and Stabilization of Kv11.1 Channels, Journal of Biological Chemistry, 10.1074/jbc.M113.531277, 289:20, (13782-13791), Online publication date: 1-May-2014. Earle N, Yeo Han D, Pilbrow A, Crawford J, Smith W, Shelling A, Cameron V, Love D and Skinner J (2014) Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome, Heart Rhythm, 10.1016/j.hrthm.2013.10.005, 11:1, (76-82), Online publication date: 1-Jan-2014. Tester D, Schwartz P and Ackerman M (2013) Congenital Long QT Syndrome Electrical Diseases of the Heart, 10.1007/978-1-4471-4881-4_27, (439-468), . NAWATHE P, KRYUKOVA Y, OREN R, MILANESI R, CLANCY C, LU J, MOSS A, DIFRANCESCO D and ROBINSON R (2013) An LQTS6 MiRP1 Mutation Suppresses Pacemaker Current and is Associated with Sinus Bradycardia, Journal of Cardiovascular Electrophysiology, 10.1111/jce.12163, 24:9, (1021-1027), Online publication date: 1-Sep-2013. Lee Y, Kwon B, Kim G, Oh S, Bae E, Park S and Noh C (2013) Long QT Syndrome: a Korean Single Center Study, Journal of Korean Medical Science, 10.3346/jkms.2013.28.10.1454, 28:10, (1454), . Clauss S, Wakili R, Steinbeck G and Kääb S (2012) Provocative Testing for Arrhythmias Electrophysiological Disorders of the Heart, 10.1016/B978-1-4377-0285-9.00072-7, (973-983), . Perrin M, Green M, Redpath C, Nery P, Keren A, Beanlands R and Birnie D (2011) Greater response to cardiac resynchronization therapy in patients with true complete left bundle branch block: a PREDICT substudy, Europace, 10.1093/europace/eur381, 14:5, (690-695), Online publication date: 1-May-2012. Bhatia A, Sra J and Akhtar M (2012) Repolarization Syndromes, Current Problems in Cardiology, 10.1016/j.cpcardiol.2012.03.004, 37:8, (317-362), Online publication date: 1-Aug-2012. Roberts A, Nixon C, Steward C, Gauvreau K, Maisenbacher M, Fletcher M, Geva J, Byrne B and Spencer C (2012) The Barth Syndrome Registry: Distinguishing disease characteristics and growth data from a longitudinal study, American Journal of Medical Genetics Part A, 10.1002/ajmg.a.35609, 158A:11, (2726-2732), Online publication date: 1-Nov-2012. Hamilton R (2011) Tinker, tailor: Foretelling the future in long QT syndrome, Heart Rhythm, 10.1016/j.hrthm.2011.06.034, 8:10, (1544-1545), Online publication date: 1-Oct-2011. Rowan S and Darbar D (2011) Genetic and Molecular Basis of Arrhythmias Management of Car
Referência(s)